Kymera Therapeutics, Inc. (KYMR): Total Liabilities
$163.15M
As of 2025-12-31
$136.19M
As of 2026-06-30
+13.0%
3-year compound annual growth
-4.3%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $163.15M | +14.6% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $142.42M | -21.2% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $180.79M | +60.0% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $112.98M | -22.8% | 2024-02-22, Balance as of period end |
| 2021-12-31 | $146.27M | -28.0% | 2023-02-23, Balance as of period end |
| 2020-12-31 | $203.29M | +147.8% | 2022-02-24, Balance as of period end |
| 2019-12-31 | $82.03M | n/a | 2021-03-11, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $163.15M | +14.6% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $74.01M | -6.2% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $56.20M | -39.8% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $159.25M | -23.2% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $102.49M | -23.3% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $104.17M | -16.2% |
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | $35.08M | -31.0% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $62.17M | -22.3% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $576.73M | +101.9% |
Compare KYMR, SGMOQ, VYGR, EDIT side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗